RenovoRx Receives Nasdaq Deficiency Notice for Failing Minimum Bid Price Requirement

summarizeSummary

RenovoRx, Inc. received a Nasdaq deficiency notice for failing to maintain the $1.00 minimum bid price, initiating a 180-day period to regain compliance and avoid potential delisting.

check_boxKey Events · Corporate Governance and Compliance · RNXT

• Nasdaq Deficiency Notice Received

  On December 31, 2025, RenovoRx, Inc. received a notice from Nasdaq indicating non-compliance with the $1.00 minimum bid price requirement (Nasdaq Listing Rule 5550(a)(2)) due to its common stock trading below this threshold for 32 consecutive business days.

• Initial Compliance Period Granted

  The company has an initial 180-calendar day period, until June 30, 2026, to regain compliance. To do so, the closing bid price of its common stock must be $1.00 or more for a minimum of ten consecutive business days.

• Potential for Extended Compliance and Delisting Risk

  If compliance is not met by June 30, 2026, the company may be eligible for an additional 180-day period if it meets other listing standards and intends to cure the deficiency, potentially through a reverse stock split. Failure to regain compliance could lead to delisting from Nasdaq.

auto_awesomeAnalysis · RNXT · Life Sciences

RenovoRx, Inc. has received a critical deficiency notice from Nasdaq due to its common stock trading below the $1.00 minimum bid price for 32 consecutive business days. This is a significant event for the company, as failure to regain compliance could lead to delisting from The Nasdaq Capital Market, severely impacting liquidity and investor confidence. While there is an initial 180-day compliance period, and potentially a second, the company will likely need to execute a reverse stock split if the price does not naturally recover, which is often dilutive and can be perceived negatively by the market. Investors should monitor the company's stock price performance closely and any plans to address this deficiency.